(Q43299753)

18 November 2017

title

Assessment of inter-individual variability in predicted phenytoin clearance (English)

1 reference

18 November 2017

1 reference

Sebastian Polak

2

0 references

Matt Doogue

object named as

Matthew P Doogue

series ordinal

3

0 references

John Miners

object named as

John O Miners

series ordinal

5

0 references

Amin Rostami-Hodjegan

object named as

Amin Rostami-Hodjegan

0 references

author name string

Thomas M Polasek

series ordinal

1

1 reference

18 November 2017

publication date

1 December 2009

1 reference

European Journal of Clinical Pharmacology

18 November 2017

published in

1 reference

18 November 2017

volume

65

1 reference

18 November 2017

issue

12

1 reference

18 November 2017

page(s)

1203-1210

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-009-0703-y

18 November 2017

exact match

0 references

cites work

Oral phenytoin pharmacokinetics during omeprazole therapy

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00228-009-0703-Y

Pharmacokinetics of a single dose of phenytoin in man measured by radioimmunoassay

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00228-009-0703-Y

Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite

21 January 2018

1 reference

12 December 2020

Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability

1 reference

12 December 2020

Reduction of absorption of digoxin, phenytoin and aspirin by activated charcoal in man

1 reference

12 December 2020

Influence of food on the absorption of phenytoin in man

1 reference

12 December 2020

Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes

1 reference

12 December 2020

Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin

1 reference

12 December 2020

A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recogn

1 reference

12 December 2020

The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example

1 reference

12 December 2020

Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine

1 reference

12 December 2020

The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities.

1 reference

12 December 2020

Phenytoin auto-induction

1 reference

12 December 2020

Phenytoin: Pharmacokinetics and bioavailability

1 reference

12 December 2020

Metabolic disposition of diphenylhydantoin in normal human subiects following intravenous administration

1 reference

12 December 2020

Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers.

1 reference

12 December 2020

Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches

1 reference

12 December 2020

Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: implications for clinical correlation

1 reference

12 December 2020

Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance.

1 reference

12 December 2020

Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation

1 reference

12 December 2020

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

1 reference

12 December 2020

The Simcyp population-based ADME simulator

1 reference

12 December 2020

Clinical Pharmacokinetics of Phenytoin

1 reference

12 December 2020

Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans

1 reference

12 December 2020

Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin

1 reference

12 December 2020

The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9.

1 reference

12 December 2020

Variability in the bioavailability of phenytoin capsules in males and females

1 reference

12 December 2020

Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding

1 reference

12 December 2020

Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo

1 reference

12 December 2020

Phenytoin auto-induction? Case reports

1 reference

12 December 2020

Co-regulation of phenytoin and tolbutamide metabolism in humans

1 reference

12 December 2020

Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans

1 reference

12 December 2020

Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

1 reference

12 December 2020

10.1007/S00228-009-0703-Y

Identifiers

DOI

1 reference

18 November 2017

1 reference